Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621.
O'Brien, MM; Ji, L; Shah, NN; Rheingold, SR; Bhojwani, D; Yuan, CM; Xu, X; Yi, JS; Harris, AC; Brown, PA; et al.
(2022)
40:956-967.
High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial.
Hitzler, J; Alonzo, T; Gerbing, R; Beckman, A; Hirsch, B; Raimondi, S; Chisholm, K; Viola, S; Brodersen, L; Loken, M; et al.
Blood.
2021;
138:2337-2346.
Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effective.
Rubinstein, JD; Shah, R; Breese, EH; Burns, KC; Mangino, JL; Norris, RE; Lee, L; Mizukawa, B; O'Brien, MM; Phillips, CL; et al.
Pediatric Blood and Cancer.
2021;
68.
Chimeric Antigen Receptor T Cell Therapy in Patients with Multiply Relapsed or Refractory Extramedullary Leukemia.
Rubinstein, JD; Krupski, C; Nelson, AS; O'Brien, MM; Davies, SM; Phillips, CL.
Biology of Blood and Marrow Transplantation.
2020;
26:e280-e285.
How the COG is Approaching the High-Risk Patient with ALL: Incorporation of Immunotherapy into Frontline Treatment.
Gupta, S; Maude, SL; O'Brien, MM; Rau, RE; McNeer, JL.
Clinical Lymphoma, Myeloma and Leukemia.
2020;
20 Suppl 1:S8-S11.
Reducing acute kidney injury in pediatric oncology patients: An improvement project targeting nephrotoxic medications.
Young, J; Dahale, D; Demmel, K; O'Brien, M; Geller, J; Courter, J; Haslam, DB; Danziger-Isakov, L; Goldstein, SL.
Pediatric Blood and Cancer.
2020;
67.
Methylation profiling of hypomethylating agent response and treatment failure in pediatric and young adult MDS/AML.
Jones, LM; O'Brien, MM; Breese, EH; Absalon, M; Burns, KC; Grimley, M; Mizukawa, B; Lee, LH; Perentesis, JP; Phillips, CL.
Journal of Clinical Oncology.
2020;
38:e22502-e22502.
Evaluation of CD22 modulation as a mechanism of resistance to inotuzumab ozogamicin (InO): Results from central CD22 testing on the Children’s Oncology Group (COG) phase II trial of INO in children and young adults with CD22+ B-acute lymphoblastic leukemia (B-ALL).
Shah, NN; O'Brien, MM; Yuan, C; Ji, L; Xu, X; Rheingold, SR; Bhojwani, D; Yi, J; Harris, A; Brown, PA; et al.
Journal of Clinical Oncology.
2020;
38:10519-10519.
Experience with ponatinib in paediatric patients with leukaemia.
Rossoff, J; Huynh, V; Rau, RE; Macy, ME; Sulis, ML; Schultz, KR; Burke, MJ; Athale, U; O'Brien, MM; Jr, GJ J; et al.
British Journal of Haematology.
2020;
189:363-368.
Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group.
Horton, TM; Whitlock, JA; Lu, X; O'Brien, MM; Borowitz, MJ; Devidas, M; Raetz, EA; Brown, PA; Carroll, WL; Hunger, SP.
British Journal of Haematology.
2019;
186:274-285.